Patients should disclose a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney disease or dehydration risk, use of diabetes medications such as insulin or sulfonylureas, pregnancy or plans for pregnancy, any personal or family history of medullary thyroid carcinoma or MEN2, and a history of diabetic retinopathy
If future trials are registered, the key details would include population, route, formulation, dose, endpoints, adverse events, and comparator group [2]
You may notice some unusual sensations in your body, but nothing too drastic or overwhelming
Orlistat, which reduces fat absorption, is available but may exacerbate diarrhoea in UC patients and is contraindicated in chronic malabsorption and cholestasis, which may affect some IBD patients
or ii) by one-way ANOVA followed by a KruskalWallis nonparametric test ( a )